BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35657688)

  • 1. The Liver-α-Cell Axis in Health and in Disease.
    Richter MM; Galsgaard KD; Elmelund E; Knop FK; Suppli MP; Holst JJ; Winther-Sørensen M; Kjeldsen SAS; Wewer Albrechtsen NJ
    Diabetes; 2022 Sep; 71(9):1852-1861. PubMed ID: 35657688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
    Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
    Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
    Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
    Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Liver-α-Cell Axis and Type 2 Diabetes.
    Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
    Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 100 years of glucagon and 100 more.
    Wewer Albrechtsen NJ; Holst JJ; Cherrington AD; Finan B; Gluud LL; Dean ED; Campbell JE; Bloom SR; Tan TM; Knop FK; Müller TD
    Diabetologia; 2023 Aug; 66(8):1378-1394. PubMed ID: 37367959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease.
    Winther-Sørensen M; Holst JJ; Wewer Albrechtsen NJ
    Curr Opin Lipidol; 2023 Feb; 34(1):27-31. PubMed ID: 36373738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine-induced glucagon secretion and glucagon-induced enhancement of amino acid catabolism are not influenced by ambient glucose levels in mice.
    Maruszczak K; Rasmussen C; Ceutz FR; Ørgaard A; Elmelund E; Richter MM; Holst JJ; Winther-Sørensen M; Wewer Albrechtsen NJ
    Am J Physiol Endocrinol Metab; 2022 Sep; 323(3):E207-E214. PubMed ID: 35830690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between glucose and the liver-alpha cell axis - A systematic review.
    Pixner T; Stummer N; Schneider AM; Lukas A; Gramlinger K; Julian V; Thivel D; Mörwald K; Mangge H; Dalus C; Aigner E; Furthner D; Weghuber D; Maruszczak K
    Front Endocrinol (Lausanne); 2022; 13():1061682. PubMed ID: 36686477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.
    Suppli MP; Bagger JI; Lund A; Demant M; van Hall G; Strandberg C; Kønig MJ; Rigbolt K; Langhoff JL; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2020 Jun; 69(6):1090-1099. PubMed ID: 31974144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon Receptor Signaling and Glucagon Resistance.
    Janah L; Kjeldsen S; Galsgaard KD; Winther-Sørensen M; Stojanovska E; Pedersen J; Knop FK; Holst JJ; Wewer Albrechtsen NJ
    Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases.
    Hædersdal S; Andersen A; Knop FK; Vilsbøll T
    Nat Rev Endocrinol; 2023 Jun; 19(6):321-335. PubMed ID: 36932176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
    Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
    Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE; Gluud L; Holst JJ; Knop FK; Vilsbøll T
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a glucagon sensitivity test in humans: Pilot data and the GLUSENTIC study protocol.
    Kjeldsen SAS; Richter MM; Jensen NJ; Nilsson MSD; Heinz N; Nybing JD; Linden FH; Høgh-Schmidt E; Boesen MP; Madsbad S; Vilstrup H; Schiødt FV; Møller A; Nørgaard K; Schmidt S; Rashu EB; Gluud LL; Haugaard SB; Holst JJ; Rungby J; Wewer Albrechtsen NJ
    Peptides; 2023 Mar; 161():170938. PubMed ID: 36596314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Primary Role for α-Cells as Amino Acid Sensors.
    Dean ED
    Diabetes; 2020 Apr; 69(4):542-549. PubMed ID: 31653720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic activation of α-cell glucokinase in mice causes enhanced glucose-suppression of glucagon secretion during normal and diabetic states.
    Bahl V; Lee May C; Perez A; Glaser B; Kaestner KH
    Mol Metab; 2021 Jul; 49():101193. PubMed ID: 33610858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis.
    Pedersen JS; Rygg MO; Kristiansen VB; Olsen BH; Serizawa RR; Holst JJ; Madsbad S; Gluud LL; Bendtsen F; Wewer Albrechtsen NJ
    Hepatol Commun; 2020 Nov; 4(11):1610-1623. PubMed ID: 33163832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1.
    Perry RJ
    Diabetes; 2022 Sep; 71(9):1834-1841. PubMed ID: 35657697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin.
    Besse-Patin A; Jeromson S; Levesque-Damphousse P; Secco B; Laplante M; Estall JL
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4285-4290. PubMed ID: 30770439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.